HIV Mutation Detail Information

> M184V Search Result

Mutation Information

Mutation Site	M184V
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Country	Swiss

Literature Information

PubMed PMID	33170863
Disease	HIV infection/AIDS
Published Year	2020
Journal	PLoS medicine
Title	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Author	Sculier D,Wandeler G,Yerly S,Marinosci A,Stoeckle M,Bernasconi E,Braun DL,Vernazza P,Cavassini M,Buzzi M,Metzner KJ,Decosterd LA,Günthard HF,Schmid P,Limacher A,Egger M,Calmy A,Swiss HIV Cohort Study (SHCS).
Evidence	Patients with only a transmitted M184V mutation became eligible from 27 June 2017, following a protocol amendment, in an effort to include individuals with transmitted nucleoside reverse transcriptase inhibitor (NRTI)-selected mutations.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation